



Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics

Ina Giegling, Ladislav Hosak, Rainald Mössner, Alessandro Serretti, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. DeLisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M. Nöthen, Jorge Ospina-Duque, Michael J. Owen, Peter Propping, YongYong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Michael C. O'Donovan & Dan Rujescu

To cite this article: Ina Giegling, Ladislav Hosak, Rainald Mössner, Alessandro Serretti, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. DeLisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M. Nöthen, Jorge Ospina-Duque, Michael J. Owen, Peter Propping, YongYong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Michael C. O'Donovan & Dan Rujescu (2017): Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics, *The World Journal of Biological Psychiatry*, DOI: [10.1080/15622975.2016.1268715](https://doi.org/10.1080/15622975.2016.1268715)

To link to this article: <http://dx.doi.org/10.1080/15622975.2016.1268715>



Published online: 23 Jan 2017.



Submit your article to this journal [↗](#)



View related articles [↗](#)










View Crossmark data [↗](#)



WFSBP CONSENSUS PAPER

Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics

Ina Giegling^{a,b} , Ladislav Hosak^c, Rainald Mössner^d, Alessandro Serretti^e , Frank Bellivier^{f,g},
Stephan Claes^{h,i}, David A. Collier^{j,k} , Alejo Corrales^l, Lynn E. DeLisi^{m,n}, Carla Gallo^o, Michael Gill^p,
James L. Kennedy^{q,r,s,t} , Marion Leboyer^{u,v,w,x}, Wolfgang Maier^y, Miguel Marquez^z,
Isabelle Massat^{aa,ab,ac,ad}, Ole Mors^{ae,af}, Pierandrea Muglia^{ag}, Markus M. Nöthen^{ah,ai}, Jorge Ospina-Duque^{aj},
Michael J. Owen^{ak,al}, Peter Propping^{am}, YongYong Shi^{an,ao,ap}, David St Clair^{aq}, Florence Thibaut^{ar} ,
Sven Cichon^{ah,ai,as,at} , Julien Mendlewicz^{au}, Michael C. O'Donovan^{ak,al} and Dan Rujescu^{a,b} 

^aDepartment of Psychiatry, Psychotherapy, and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany; ^bDepartment of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany; ^cDepartment of Psychiatry, Charles University, Faculty of Medicine and University Hospital in Hradec Králové, Prague, Czech Republic; ^dDepartment of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany; ^eDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; ^fFondation Fondamental, Créteil, France AP-HP, GH Saint-Louis-Lariboisière-Fernand-Widal, Pôle Neurosciences, Paris, France; ^gEquipe 1, Université Paris Diderot, Paris, France; ^hGRASP-Research Group, Department of Neuroscience, University of Leuven, Leuven, Belgium; ⁱDepartment of Neurosciences, University Psychiatric Center KU Leuven, Leuven, Belgium; ^jSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK; ^kEli Lilly and Company Ltd, Erl Wood Manor, Surrey, UK; ^lArgentinean Association of Biological Psychiatry, National University, UNT, Buenos Aires, Argentina; ^mVA Boston Health Care System, Brockton, MA, USA; ⁿDepartment of Psychiatry, Harvard Medical School, Boston, MA, USA; ^oDepartamento de Ciencias Celulares y Moleculares, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru; ^pNeuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin, Ireland; ^qNeurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada; ^rCentre for Addiction and Mental Health, Campbell Family Mental Health Research Institute, Toronto, ON, Canada; ^sDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada; ^tCollaborative Program in Neuroscience, Institute of Medical Science, University of Toronto, Toronto, ON, Canada; ^uEquipe Psychiatrie Translationnelle, Faculté de Médecine, Université Paris-Est Créteil, Inserm U955, Créteil, France; ^vDHU Pe-Psy, Pôle de Psychiatrie et d'Addictologie, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France; ^wPôle de Psychiatrie, Hôpital Albert Chenevier, Créteil, France; ^xFondation FondaMental, Créteil, France; ^yDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; ^zAsistencia, Docencia e Investigación en Neurociencia, Buenos Aires, Argentina; ^{aa}UNI - ULB Neurosciences Institute, ULB, Bruxelles, Belgium; ^{ab}National Fund of Scientific Research (FNRS), Bruxelles, Belgium; ^{ac}Laboratory of Experimental Neurology, ULB, Bruxelles, Belgium; ^{ad}UR2NF - Neuropsychology and Funcional Neuroimaging Research Unit, Centre de Recherche Cognition et Neurosciences, Université Libre de Bruxelles (ULB), Bruxelles, Belgium; ^{ae}Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark; ^{af}The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark; ^{ag}UCB Biopharma, Brussels, Belgium; ^{ah}Head, Institute of Human Genetics, University of Bonn, Bonn, Germany; ^{ai}Department of Genomics, Life and Brain Center, Bonn, Germany; ^{aj}Grupo de Investigación en Psiquiatría, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia; ^{ak}MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK; ^{al}National Centre for Mental Health, Cardiff University, Cardiff, UK; ^{am}University of Bonn, Bonn, Germany; ^{an}Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China; ^{ao}Shandong Provincial Key Laboratory of Metabolic Disease, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China; ^{ap}Institute of Social Cognitive and Behavioral Sciences, Shanghai Jiao Tong University, Shanghai, P.R. China; ^{aq}Department of Psychiatry, University of Aberdeen, Institute of Medical Sciences, Aberdeen, UK; ^{ar}INSERM U 894 Centre Psychiatry and Neurosciences, University Hospital Cochin (Site Tarnier), University Sorbonne Paris Cité (Faculty of Medicine Paris Descartes), Paris, France; ^{as}Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; ^{at}Genomic Imaging, Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany; ^{au}Laboratoire de Psychologie Médicale, Centre Européen de Psychologie Médicale, Université Libre de Bruxelles and Psy Pluriel, Brussels, Belgium

ABSTRACT

Objectives: Schizophrenia is a severe psychiatric disease affecting about 1% of the general population. The relative contribution of genetic factors has been estimated to be up to 80%. The mode of inheritance is complex, non-Mendelian, and in most cases involving the combined action of large numbers of genes.

Methods: This review summarises recent efforts to identify genetic variants associated with schizophrenia detected, e.g., through genome-wide association studies, studies on copy-number variants or next-generation sequencing.

ARTICLE HISTORY

Received 18 November 2016
Accepted 29 November 2016

KEYWORDS

Genetics; schizophrenia; psychiatry; psychosis; genome; sequencing; polygenic; genetic

Results: A large, new body of evidence on genetics of schizophrenia has accumulated over recent years. Many new robustly associated genetic loci have been detected. Furthermore, there is consensus that at least a dozen microdeletions and microduplications contribute to the disease. Genetic overlap between schizophrenia, other psychiatric disorders, and neurodevelopmental syndromes raised new questions regarding the current classification of psychiatric and neurodevelopmental diseases.

Conclusions: Future studies will address especially the functional characterisation of genetic variants. This will hopefully open the doors to our understanding of the pathophysiology of schizophrenia and other related diseases. Complementary, integrated systems biology approaches to genomics, transcriptomics, proteomics and metabolomics may also play crucial roles in enabling a precision medicine approach to the treatment of individual patients.

Heritability of schizophrenia

Evidence for a strong genetic component to the aetiology of schizophrenia was first demonstrated by classical genetic epidemiology in the form of family, twin, and adoption studies (Cardno & Gottesman 2000; Sullivan et al. 2003; Wray & Gottesman 2012) and has more recently been confirmed by molecular genetics (Gusev et al. 2014). While the lifetime risk in the population for developing schizophrenia varies within countries, the overall rate is estimated at around 0.5–1%. Risk for an individual increases non-linearly with the degree of genetic relatedness to a person suffering from the disorder; for third-degree relatives it is approximately 2% rising to approximately 9% for first-degree relatives, or, in the case of the children of two affected parents, around 27% (Gottesman et al. 2010). For monozygotic (MZ) twins, the concordance rate is approximately 50% (Lichtenstein et al. 2006, 2009). For adopted children with a biological parent with schizophrenia the risk of developing schizophrenia is 6–10 times higher than in the general population (Shih et al. 2004).

Altogether, the heritability of schizophrenia is estimated to be between 64 and 81% (Sullivan et al. 2003; Lichtenstein et al. 2009). Large amounts of genetic variations contribute to the disorder making the mode of inheritance complex. Only a small proportion of these DNA variants have been identified so far and it is now clear that genetic susceptibility is the result of many common variants of low penetrance, some rare variants of moderately high penetrance (Kendler 2015; Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014) as well as presumably uncommon and rare variants of small to moderately high effect that cannot be detected individually in sample sizes studied to date. Progress in understanding the genetics of complex disease is closely tied to technological developments. The potential of those technologies, which include arrays capable of detecting millions of common variants as well as large structural variations, and newer sequencing technologies, has led to an explosion of findings in human genetics

as a field. In parallel with the technological capabilities, approaches to complex disease genetics has extended from linkage studies to candidate association studies, genome-wide association (GWA) studies and, currently, to exome or whole-genome sequencing.

Linkage studies

Linkage studies are based on the fact that genetic traits located closely together on a chromosome are more likely to segregate together, that is, be co-inherited in families, than are genetic variants located further apart. Linkage is most powerful under models of genetic transmission whereby genes of major effect cause disease in all affected family members. For common diseases this may not be the case and multiply affected families may mimic Mendelian architecture. Early linkage studies suggested involvement of a major risk allele on chromosome 5 [5q11.2 to 5q13.3] (Bassett et al. 1988; Sherrington et al. 1988), but that finding has not been extensively replicated (Kennedy et al. 1988; St Clair et al. 1989). One of the largest meta-analyses was provided by Ng et al. (2009), including 32 independent genome-wide linkage scans and a total of 3,255 pedigrees and 7,413 genotyped cases affected with schizophrenia or related disorders. The results pointed to evidence for linkage on 5q (142–168 Mb) and 2q (103–134 Mb). A secondary analysis restricted to the studies based on families of European ancestry provided suggestive evidence for linkage on chromosome 8p (16–33 Mb) (Ng et al. 2009). So far these linkage studies failed to conclusively identify any susceptibility gene, although some recent meta-analyses showed partial overlap for 5p14.1 and 10q26.12 (Vieland et al. 2014).

Candidate gene studies

As methods of DNA amplification were developed, association studies became more feasible (Mullis et al. 1986; Mullis et al. 1994). These were mainly based on

case-control analysis of single-nucleotide polymorphisms (SNPs) within candidate genes derived from neurobiological hypotheses. Gatt et al. (2015) presented a review of meta-analyses based on candidate genes. From a total of 97 variants reported in schizophrenia, the strongest evidence ($P < 0.001$) was reported for genes involved in the modulation of dopamine (e.g., COMT, DRD2, DRD3 and DRD4), glutamate (e.g., DAOA, GABRB2 and NRG1), neuronal development and function (e.g., AHI1, MTHFR, RELN and TRKA), serotonin neurotransmission (HTR2A, SLC6A4 and TPH1) or the immune system (IL1B). The authors focussed not only on schizophrenia but on specific mental disorders that have core disruptions to emotional and cognitive function and contribute most to burden of illnesses including major depressive disorder (MDD), anxiety disorders (including panic disorder and obsessive compulsive disorder), schizophrenia, bipolar disorder (BD) and attention deficit hyperactivity disorder (ADHD). A total of 1,519 meta-analyses were conducted across 157 studies reporting multiple genes implicated in one or more of the five disorders. A total of 134 genes (206 variants) were identified as significantly associated risk variants. Thirteen genetic variants were shared in common between two or more disorders (APOE, ACE, BDNF, COMT, DAOA, DAT1, DRD4, SLC6A4, HTR1A, MTHR, MTHR and TPH1) demonstrating evidence for pleiotropy (Gatt et al. 2015). Nevertheless, the significance threshold was not as strict as applied for genome-wide studies indicating that there could be spurious associations among these genes. Another drawback is that there tends to be a publication bias towards original articles reporting on positive findings, and only these could be used for meta-analyses.

GWA studies

Due to technical developments in array genotyping, research is no longer limited to testing a small number of candidate variants in sample sizes that are underpowered to detect the small effect sizes of common variants we now know to typically associate with complex diseases. Array genotyping instead makes it possible to conduct GWA studies which extract information for more than 10 million SNPs per sample in a single experiment. That implies that stringent correction for multiple testing has to be performed and, as discussed later, power to detect associations at the genome wide significance threshold is incomplete even in the largest studies to date and therefore many of the hits not reaching genome-wide significance may turn out to be true associations in larger samples.

From a technical point of view, association with a locus not necessarily implicates a particular gene but rather a region, each with a small effect size.

The first GWA studies on schizophrenia performed in 2007/2008 were clearly underpowered, including 178 cases, 144 controls (Lencz et al. 2007) and 738 cases, 733 controls, respectively (Sullivan et al. 2008). The problem of insufficient power to detect genome-wide significant markers directly was addressed by O'Donovan et al. (2008) by using top markers ($P < 10^{-5}$) from an initial GWA study on 479 cases and 2,937 controls, as candidates to be followed up in an independent replication cohort of up to 6,829 cases and 9,897 controls. Three out of 12 loci were shown to have a strong independent support, and the overall pattern of replication was unlikely to occur by chance. Most interestingly, evidence for association at the top SNP which maps to a locus containing the gene ZNF804A, strengthened when the affected phenotype included BD, which challenges the traditional diagnostic boundaries (O'Donovan et al. 2008). The study of Stefansson et al. (2009) used basically the same approach. A GWA study performed with 2,663 cases and 13,498 controls from eight European locations within the SGENE+ consortium revealed no genome-wide significant signal. The findings for the top 1,500 SNPs were combined with results for these SNPs (or proxies) from two independent cohorts (2,602 cases/2,885 controls from the International Schizophrenia Consortium (ISC), and 2,687 cases/2,656 controls from the European-American portion of the Molecular Genetics of Schizophrenia Consortium (MGS)). The most significant association signals were followed up in 5,013 cases and 15,559 controls from four additional sample sets from Europe, leading to the identification of three novel candidate schizophrenia loci: NRGRN (coding for neurogranin), TCF4 (coding for transcription factor 4) and the major histocompatibility complex (MHC) region (Stefansson et al. 2009). At the same time the ISC and the MGS reported GWA studies of the MHC region (International Schizophrenia Consortium 2009; Shi et al. 2009).

As power and, therefore, sample size is the most limiting factor in GWA studies, a new consortium, the Psychiatric Genome Wide Association Study Consortium (PGC) started a highly successful initiative to collect existing GWAS data from as many schizophrenia cases and controls as possible. The first publication in 2011 contained a total sample of more than 51,000 individuals of European ancestry. Genome-wide significant association was identified for seven loci, five representing novel loci (1p21, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33) and two with previous

implication (6p21.32-p22.1 and 18q21.2). The strongest new finding was for rs1625579, located within an intron of a putative primary transcript of microRNA 137 (MIR137), which is involved in regulation of neuronal development. Supporting a role of MIR137 dysregulation as a previously unknown aetiological mechanism in schizophrenia was the finding that additional markers in four predicted targets of MIR137 also showed genome-wide significant P values. Combining the schizophrenia sample with a BD sample (16,374 cases and 14,044 controls) led to the identification of three loci that confer susceptibility to both BD and schizophrenia, i.e. CACNA1C, ANK3 and the ITIH3-ITIH4 region (Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium 2011). Given the large sample, the yield of five new loci might be considered disappointing, but a follow-up study by Hamshere et al. (2013) demonstrated, in an independent sample, that the vast majority of the 81 associations in the PGC study that met an intermediate threshold of significance ($P < 10^{-5}$) represented true associations, providing a robust rationale for expanding the GWAS to larger samples. Moreover, when they combined their small (in current GWAS terms) sample with those of the PGC, they identified three additional genome wide significant loci, stressing the cumulative value of building up the large datasets.

In 2013, Ripke et al. re-analysed the PGC schizophrenia data using 1000 Genomes imputation and conducted a study comprising an initial analysis based on 5,001 cases and 6,243 controls followed by meta-analysis with previous schizophrenia GWAS data (8,832 cases and 12,067 controls) and finally by replication of SNPs in up to 168 genomic regions in independent samples (7,413 cases, 19,762 controls and 581 parent-offspring trios). Of the 22 loci associated at genome-wide significance level, previous reports had been published for seven loci with schizophrenia alone (MHC, WBP1L/C10orf26, DPYD-MIR137, SDCCAG8 and MMP16, CACNA1C, and ITIH3-ITIH4), one with a combined phenotype consisting of schizophrenia and BD (CACNB2), and one with BD (NCAN). The remaining 13 newly identified loci consisted of regions including MAD1L1, TSNARE1, SNX19, QPCT, SLC06A1, ZEB2, FONG, C2orf82, AKT3, C12orf65 as well as loci near GRIA1, TCF4 and ZSWIM6. Examination of candidate regions suggested the involvement of neuronal calcium signalling, the MHC region, which showed the highest significance, MIR137 (dys)regulation via target sites and epigenetic regulation, and development through long intergenic non-coding RNAs (Ripke et al. 2013).

The latest and largest GWAS on schizophrenia was published in 2014 by the schizophrenia PGC team

featuring a multi-stage GWA study of 36,989 cases and 113,075 controls. A total of 128 associations in 108 independent loci were identified, with the strongest associated locus being an extended region of chromosome 6 containing a large number of genes including the MHC region ($P = 3.48 \times 10^{-31}$) (Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014; bioinformatic data for the 108 loci is found in the Supplementary Information). Novel associations were observed for 83 loci not necessarily implicating a gene but rather a region. Associations were enriched among genes showing epigenetic markers indicative of expression in the brain. Interestingly, a number of loci containing former known candidate genes like DRD2 and several genes involved in glutamatergic neurotransmission (GRM3, GRIN2A, SRR and GRIA1) reached genome-wide significance, supporting gene products of known and potential therapeutic relevance to schizophrenia, and broadly supporting leading pathophysiological hypotheses of the disorder. The PGC study also reported evidence that associations were enriched in genes expressed in tissues relevant to immunity, although a more sophisticated re-analysis of the data failed to support this, confirming only the enrichment for brain-expressed genes (Finucane et al. 2015).

The most consistent result throughout the GWAS of schizophrenia is the association to the extended MHC region. This was found in several independent samples of moderate (International Schizophrenia Consortium 2009; Stefansson et al. 2009; Shi et al. 2009; Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2 2012) to large sizes (Ripke et al. 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). Interestingly, allelic variation at the Complement component C4A locus, which is located in the MHC region, explains part of the heritability of schizophrenia. There is evidence that C4A is involved in synaptic plasticity, providing a potential functional explanation for the involvement of the immune system in schizophrenia pathogenesis (Sekar et al. 2016).

Polygenic risk scores

GWA studies have provided strong evidence that psychiatric disorders are highly polygenic, with a genetic architecture consisting of many common genetic variants. As discussed later, rare risk variants are also involved. To achieve genome-wide significance, P values have to pass a stringent threshold. It is estimated that in common variant GWAS, around 1 million independent association tests are conducted and the threshold for significance after multiple testing is

therefore 0.05/1 million or 5×10^{-8} (NCI-NHGRI Working Group on Replication in Association Studies 2007). Attaining this for alleles of small effect requires very large sample sizes of many tens of thousands of patients and controls. Interestingly, although the total number of loci surpassing the genome-wide significance threshold is often small (or even zero in small studies), the GWAS typically yield many more associations with small P values than expected by chance. This finding is consistent with a polygenic genetic architecture, and provided the impetus for new statistical methods (Wray et al. 2014). Two frequently applied methods are “polygenic risk scoring” and “estimating variance explained by all SNPs” (for details see Wray et al. 2014).

The first genomic profile risk scoring for schizophrenia was reported by the International Schizophrenia Consortium (2009). This study provides evidence for a polygenic component to risk of schizophrenia involving at least 1,000 common alleles of very small effect (Nagelkerke $R^2 = 0.032$; a measure of variance in case-control status explained). Furthermore, the risk profile score was also associated with risk of BD, but not to multiple non-psychiatric diseases.

Within the much larger PGC-schizophrenia sample the R^2 increased to 0.184. Under the assumption of a liability-threshold model, a lifetime risk of 1%, independent SNP effects and adjusting for case-control ascertainment, the polygenic risk score explained about 7% of variation on the liability scale to schizophrenia across the samples, about half of which (3.4%) is explained by genome-wide significant loci in this study (Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). Many other studies using polygenic risk scores have been conducted, including cross-disorder overlaps, schizophrenia symptoms or phenotypes (for review see Wray et al. 2014). Given that polygenic scores represent biomarkers (Schmitt et al. 2016) that tap into liability to the disorder even in unaffected people, we anticipate they will become more and more important in research, although to date, they do not capture enough risk to be clinically useful.

Identification of rare risk variants before GWA studies

Up to the mid-2000s, the only genetic variant definitively known to contribute to schizophrenia was a microdeletion at chromosome 22q11.2. The deletion region contains over 40 genes including a number of plausible candidates like COMT (catechol-*O*-methyl transferase), ProDH, TBX1 and GNB1L, which are known to be involved in brain function and

neurodevelopment (Raux et al. 2007; Squarcione et al. 2013; Schneider et al. 2014). However, despite several studies that have tried to do so, it has not proven possible to identify which gene(s) within 22q11.2 explain the link between deletion of this region and schizophrenia. Also worth noting from the pre-GWAS era is Disrupted-in-Schizophrenia-1 (DISC1), another key historical candidate gene that has been widely researched. DISC1 was identified as being disrupted by one of two chromosomal breakpoints (Millar et al. 2000) involved in a balanced translocation between chromosome 1 and chromosome 11 (1;11)(q42.1;q14.3) that co-segregates with multiple forms of psychiatric disorder in a single large Scottish pedigree (St Clair et al. 1990; Muir et al. 2008). Although the eponymous but, given the range of phenotypes exhibited in family members, somewhat inaccurately named DISC1 gene has plausibility given it has been shown to disrupt numerous important functions of the brain (Porteous et al. 2014; Randall et al. 2014), additional evidence beyond co-segregation is required to decisively implicate this gene in major mental illness.

Copy number variants identified through GWA studies

It was originally possible to link the 22q11.2 deletion to schizophrenia because the same mutation also causes a recognisable genomic syndrome called velocardiofacial syndrome (VCFS) or DiGeorge syndrome, and it had been observed that those individuals with VCFS had high rates of psychosis (Shprintzen et al. 1992; Pulver et al. 1994). In the mid-2000s, technological developments, particularly those that allow GWAS studies, started to fill the resolution gap between the traditional cytogenetic analysis (>2 Mb) and mutation analysis by DNA sequencing (<1 kb), making it possible to perform systematic scans of the genome for chromosomal microdeletions and duplications (collectively known as copy number variants or CNVs) without any prior knowledge of phenotypic comorbidity between schizophrenia and a particular genomic syndrome (see Table 1).

A number of investigators (Kirov et al. 2008; Walsh et al. 2008; Xu et al. 2008) were prompted to screen proband-parent trios for newly occurring or de novo mutations, the idea being that the loss of schizophrenia risk alleles resulting from the reduced fecundity of people with the disorder must be counter-balanced by the occurrence of new mutations unless the disorder was vanishing in the population. Early support for the involvement of CNVs was obtained in all these studies, but none was powered to convincingly implicate any

Table 1. Microdeletions and microduplications involved in schizophrenia.

		Replication ^a	Meta-Analysis ^a
Deletions			
1q21.1 ^b	Stefansson et al. 2008; International Schizophrenia Consortium 2008; Levinson et al. 2011	0.0027	4.1 × 10 ⁻¹³
2p16.3	Kirov et al. 2008; Walsh et al. 2008; Rujescu et al. 2009; Kirov et al. 2009b	7.7 × 10 ⁻⁰⁴	1.3 × 10 ⁻¹¹
3q29	Mulle et al. 2010; Levinson et al. 2011	0.074	1.5 × 10 ⁻⁹
15q11.2 ^b	Stefansson et al. 2008; Kirov et al. 2009a	0.046	2.5 × 10 ⁻¹⁰
15q13.3 ^b	Stefansson et al. 2008; International Schizophrenia Consortium 2008; Levinson et al. 2011	0.38	4.0 × 10 ⁻¹⁰
16p11.2 ^b	Walsh et al. 2008; Guha et al. 2013	1.0	0.017
17p12	Kirov et al. 2009a	0.55	0.0012
17q12	Moreno-De-Luca et al. 2010	0.52	0.0072
Duplications			
1q21.1 ^b	Levinson et al. 2011	0.35	9.9 × 10 ⁻⁵
7q11.23	Kirov et al. 2012; Mulle et al. 2014	0.35	6.9 × 10 ⁻⁵
7q36.3	Levinson et al. 2011; Vacic et al. 2011	0.99	0.27
15q11-13 ^b	Kirov et al. 2008; Ingason et al. 2011a	0.0055	5.6 × 10 ⁻⁶
16p11.2 ^b	Walsh et al. 2008; McCarthy et al. 2009; Levinson et al. 2011; Steinberg et al. 2014	2.3 × 10 ⁻⁰⁸	2.9 × 10 ⁻²⁴
16p13.11	Kirov et al. 2009a; Ingason et al. 2011b	0.056	5.7 × 10 ⁻⁵

^aRees et al. (2014), replication study: cases, $n = 6,882$; controls $n = 6,316$.

^bRegion with both deletions and duplications.

specific CNVs due to insufficient sample size. However, these were rapidly followed by two larger studies, one by the SGENE + consortium and one by the ISC. In a first step the SGENE + consortium analysed 9,878 individuals for transmission from parents to descendant (Stefansson et al. 2008). The study identified 66 novel CNVs which were tested for association in a subsequent case-control study. Three deletions (1q21.1, 15q11.2 and 15q13.3) showing nominal association in the first sample were followed-up in a second sample of 3,285 cases and 7,951 controls. The combined sample showed enrichment of all three microdeletions. Two of these, deletions at 15q13.3 (containing the nicotinic alpha 7 gene) and 1q21.1, were independently identified in the ISC study, which analysed 3,391 schizophrenia patients and 3,181 controls (International Schizophrenia Consortium 2008). Moreover, in the ISC study, compared to controls, patients with schizophrenia had a 1.15-fold increase of rare CNVs (frequency less than 1% in this study) of more than 100 kb in length. Together, these studies decisively confirmed a collective enrichment of rare CNVs in schizophrenia patients and identified specific CNVs associated with risk of the disorder. The deletion identified by SGENE + but not the ISC, that at 15q11.2, was subsequently confirmed in the ISC and other data by Kirov et al. (2009a), and overall evidence for all three loci is beyond doubt in a recent meta-analysis (Rees et al. 2014).

Additional deletions significantly associated with schizophrenia at 3q29 (Levinson et al. 2011; Mulle et al. 2010), 16p11.2 (Guha et al. 2013), 17p12 (Kirov et al. 2009a) and 17q12 (Moreno-De-Luca et al. 2010) were replicated in the meta-analysis by Rees et al. (2014), with 3q29 showing highest ORs (OR = 57.65). Additional CNV studies suggested a role for the neurexin 1 gene (NRXN1; 2p16.3). Deletions within this

gene previously associated with autism have also been reported in two families with schizophrenia (Kirov et al. 2008; Walsh et al. 2008). In a study conducted by the SGENE + consortium using 2,977 schizophrenia patients and 33,746 controls, NRXN1 CNVs (>100 kb) disrupting exons were significantly enriched in cases (0.24 vs. 0.015% in controls) with an odds ratio of 8.97 (Rujescu et al. 2009). A meta-analysis in 8,789 cases and 42,054 controls further supports these results (Kirov et al. 2009b). Significant associations with deletions were also reported by Levinson et al. (2011) and in a recent meta-analysis by Rees et al. (2014). Several studies supported not only the role of deletions but also of duplications in the development of schizophrenia. Within the SGENE + consortium, a 15q11-q13 (Ingason et al. 2011a) and a 16p13.11 duplication (Ingason et al. 2011b) were identified. Both of them, as well as a duplication at 16p11.2 (McCarthy et al. 2009; Levinson et al. 2011; Steinberg et al. 2014), were confirmed in the Rees et al. (2014) meta-analysis. Several other loci could not be confirmed by this meta-analysis and are subject of further investigation: 1q21.1 (Levinson et al. 2011), 7q11.23 associated with Williams-Beuren syndrome (Kirov et al. 2012; Mulle et al. 2014) and 7q36.3 containing VIPR2, a neuropeptide receptor gene (Levinson et al. 2011; Vacic et al. 2011).

CNVs enriched in psychosis are also involved in the pathology of other neurodevelopmental and neurological disorders, including intellectual disability, autism and seizures (Grayton et al. 2012; Grozeva et al. 2012). Within the group of 1q21.1 deletion carriers, psychiatric and behavioural abnormalities can include epilepsy, autism or ADHD (Haldeman-Englert & Jewett 1993–2016; de Kovel et al. 2010; Sanders et al. 2015). Neurexin 1 deletions are also associated with autism spectrum disorders, intellectual disability, language

delays (Schaaf et al. 2012), developmental delay or intellectual disability (Jenkins et al. 2016). Very similar overlaps are seen for the 15q11.2 region including intellectual disability, developmental delay, neurological problems, autism, attention problems and speech delay (Abdelmoity et al. 2012; Derks et al. 2013). Similarly, the 15q13.3 CNVs are present in multiple neurodevelopmental syndromes that cause intellectual disability, epilepsy and variable facial and digital dysmorphisms. Interestingly, the discovered de novo deletions in this region have also been shown to give rise to a number of other phenotypes, including abnormal EEG, significant expressive language deficits, and a spectrum of neuropsychiatric impairments that include autism, ADHD, anxiety disorder, mood disorder and cognitive impairment (Helbig et al. 2009; Pagnamenta et al. 2009; Adams et al. 2012; Williams et al. 2012; Isles et al. 2016).

Other studies have continued to pursue de novo mutations in schizophrenia (e.g., Kirov et al. 2012; Malhotra & Sebat 2012). Both provide an estimated rate for large de novo CNVs in schizophrenia of about 5%, 2–3 times higher than that of controls. Based on the meta-analysis of Rees et al. (2014) the question arises concerning the implications of the CNV findings for genetic counselling. Out of 15 previously implicated CNV loci, 11 were strongly associated in this meta-analysis. The evidence for the remaining four loci is still equivocal and requiring further investigation. These findings indicate that approximately 2.5% of individuals with schizophrenia carry at least one known pathogenic CNV. The odds ratios for schizophrenia range between approximately 2 and more than 50. As noted above, most are also found in a range of other neurodevelopmental disorders, including epilepsy (15q11.2 and 15q13.3), autism and intellectual disability. As Rees et al. (2014) postulated, a number of the pathogenic CNVs are associated with particular physical disease phenotypes including congenital heart disease (1q21.1 and 22q11.2), microcephaly (1q21.1, 3q29 and 16p11.2) and obesity (16p11.2 distal). These findings suggest that screening for CNVs should be considered at least in the case of non-brain-related physical comorbidity. These results have the potential to directly guide everyday clinical patient care (Rees et al. 2014).

Kirov et al. (2012) noted multiple de novo CNVs spanned components of the post-synaptic density (PSD). This was largely explained by enrichment for members of the *N*-methyl-D-aspartate receptor (NMDAR) and neuronal activity-regulated cytoskeleton-associated protein (ARC) postsynaptic signalling complexes; both known to be important in synaptic plasticity and cognition. They also found recurrent CNVs

affecting EHMT1, a histone methyl transferase known to directly regulate DLG family members and other components of the PSD. Large-scale follow-up case-control analyses (Pocklington et al. 2015) have confirmed the enrichments for schizophrenia-related CNVs in PSD, ARC and NMDAR complexes, and have extended this to implicate inhibitory post-synaptic GABAergic complexes, which have strong functional links in regulating synaptic plasticity with the major excitatory glutamatergic system.

As overlapping genes affected by rare variants and those localised within the associated GWAS loci also show convergence in terms of functional clustering it seems likely that common and rare variant studies are complementary rather than antagonistic, and that mechanistic studies driven by rare genetic variation will be informative for schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). The latest CNV analysis on 41,321 subjects observed a global enrichment of CNV burden ($OR = 1.11$, $P = 5.7 \times 10^{-15}$). CNV burden was especially enriched for genes associated with synaptic function ($OR = 1.68$, $P = 2.8 \times 10^{-11}$) and neurobehavioral phenotypes in mouse ($OR = 1.18$, $P = 7.3 \times 10^{-5}$). Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2 (CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium & Psychosis Endophenotypes International Consortium, 2016).

Next generation sequencing

Major developments in sequencing technology have taken place in the last years, enabling rapid and increasingly economical whole-exome or whole-genome sequencing. These sequencing methods can, e.g., be applied for case-control studies or for the detection of de novo mutations by sequencing both unaffected parents and the affected child. A study by Xu et al. (2011) sequenced the exomes of 53 trios with sporadic cases and their unaffected parents, as well as 22 unaffected controls trios. They identified 40 de novo mutations in 27 cases affecting 40 genes, including a potentially disruptive mutation in DGCR2, a gene located in the schizophrenia-predisposing 22q11.2 microdeletion region. A follow-up study by the same group sequenced 795 exomes from 231 parent-proband trios enriched for sporadic schizophrenia cases, as well as 34 unaffected trios. They observed an excess of de novo nonsynonymous single-nucleotide variants as well as a higher prevalence of gene-disruptive de novo mutations relative to controls. They found four

genes (LAMA2, DPYD, TRRAP and VPS39) affected by recurrent de novo events, which is unlikely to have occurred by chance (Xu et al. 2012). Moreover, a de novo deletion of DPYD had first been found in autism (Marshall et al. 2008).

Interestingly, a de novo mutation in another member of the laminin gene family, LAMA1 was described in another schizophrenia sequencing study reported by Girard et al. (2011).

Exome sequencing of genomic DNA carried out for 399 persons, including 105 probands with schizophrenia, 84 unaffected sibs and their 210 unaffected parents was performed by Gulsuner et al. (2013). The results suggest that disruptions of foetal prefrontal cortical neurogenesis may be critical to the pathophysiology of schizophrenia (Gulsuner et al. 2013). McCarthy et al. (2014) carried out exome sequencing on 57 trios with sporadic or familial schizophrenia. In sporadic trios, they observed an ~ 3.5 -fold increase in the proportion of nonsense de-novo mutations. Genes at these loci overlapped with genes implicated in autism (e.g., AUTS2, CHD8 and MECP2) and intellectual disability (e.g., HUWE1 and TRAPPC9), supporting a shared genetic aetiology between these disorders. Functionally, CHD8, MECP2 and HUWE1 converge on epigenetic regulation of transcription suggesting that this may be an important risk mechanism.

The largest individual de novo trios and case-control sequencing studies of schizophrenia so far were those, respectively, of Fromer et al. (2014) and Purcell et al. (2014). Fromer et al. (2014) obtained further evidence for shared genetic aetiology between schizophrenia and both intellectual disability and ASD by testing for overlap of genes affected by de novo loss-of-function mutations in schizophrenia, ASD and intellectual disability. The study shows an overlap between schizophrenia, ASD and intellectual disability at the resolution not just of loci or even individual genes, but even of mutations with similar functional (loss-of-function) effects.

Although Fromer et al. (2014) were unable to confirm the findings from some of the smaller studies that, at the genome wide level, cases are enriched for small de novo mutations, they did find that this type of mutation was overrepresented among the same complexes implicated by de novo CNVs, specifically the ARC and NMDAR complexes. Mutations were additionally enriched in messenger RNAs that are targets of fragile X mental retardation protein (FMRP). Purcell et al. (2014) identified a polygenic burden arising from very rare (frequency less than 1 in 1,000 chromosomes) mutations and that, once again, these were enriched among ARC, NMDAR and PSD protein complexes as well as FMRP targets and calcium channel complexes. Despite their size,

neither of these studies was able to implicate specific genes. However, very recently, the UK10K group, in collaboration with many of the other groups, has done so by meta-analysis of their own case-control and de novo mutation datasets with much of the data referred to above in this section. This study (Singh et al. 2016), which included a total of 4,264 schizophrenia cases, 9,343 controls and 1,077 parent-proband trios, obtained genome-wide significant association ($P = 5.6 \times 10^{-9}$) between schizophrenia and a rare loss-of-function variant in SETD1A a histone methyl-transferase, which the group also showed was implicated in other severe developmental disorders. The finding establishes histone methylation pathways in the pathogenesis of the disorder, and establishes overlap between schizophrenia and other neurodevelopmental disorders at the level of a specific highly penetrant recurrent mutation in a single gene.

Gene \times environment effects

Besides the genetics of schizophrenia, gene-environment interactions and epigenetic studies seem promising (van Dongen & Boomsma 2013; Agerbo et al. 2015; Owen et al. 2016). A gene-environment interaction (G \times E) represents a genetic influence on vulnerability to environmental factors (Rutter et al. 2006). A comprehensive review of G \times E interactions in schizophrenia was presented by van Os et al. (2008). However, so far, thorough replication of findings is rare and G \times E research still faces several conceptual and methodological challenges (EU-GEI 2014). Published environmental exposures for psychosis for which G \times E has been suggested include complications of pregnancy, paternal age, urban environment, cannabis use, migration and childhood maltreatment. Urbanicity, migration, a lack of social support and negative expressed emotions are considered as proxies for environmental stressors. Van Winkel et al. (2008) reviewed the role of psychosocial stress in the development of positive psychotic symptoms (hallucinations or delusions). The authors asserted the concept of "behavioural sensitisation", meaning that repetitive stress progressively increases the biological and behavioural (psychopathological) response to subsequent exposure. The substrate for this effect was postulated to be a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, namely elevated plasma cortisol contributing to the hypothesised final common pathway of dopamine release and sensitisation in the mesolimbic brain area. Polymorphisms of the genes related to catecholamine neurotransmission, neuroplasticity and stress activation (e.g., COMT, DA receptors, BDNF and the HPA axis) may




Figure 1. Risk factors of schizophrenia.

influence the extent of the sensitisation process though the genetic findings concerning $G \times E$ in schizophrenia are not yet widely considered to be robust. A review and meta-analysis of the role of life events in psychosis was carried out by Beards et al. (2013). The meta-analysis yielded an OR of 3.19. Miller et al. (2013) reviewed relevant human studies related to prenatal inflammation and risk of schizophrenia. The authors concluded that inflammation may be associated with abnormal neurodevelopment. Epigenetics (DNA methylation, histone/chromatin modifications and non-coding RNA) is related to potentially heritable or acquired changes in gene expression and function that are not caused by variation in the DNA sequence (Perkins et al. 2005; Szyf 2015). Epigenetic DNA status may be partially heritable, but during an individual's life may also be modified by a broad spectrum of environmental stimuli (e.g., alimentation, toxins, stress or medication) (Waterland & Jirtle 2003). They may be different in different tissues or even different regions in the brain in the same subject. They may contribute to phenotypical differences in MZ twins (Wong et al. 2005). The first studies on epigenetic mechanisms in schizophrenia aetiopathogenesis have already been performed (e.g., for review see Akbarian 2014). Based on a review, Maric and Svrakic (2012)

suggest that epigenetic misregulation of the genome and direct CNS injury are probably the main mechanisms to mediate prenatal environmental effects (e.g., viruses, ethanol or nutritional deficiency), whereas post-natal risk factors (e.g., stress, urbanicity or cannabis use) may also affect risk via potentiation of vulnerable CNS pathways implicated in schizophrenia (Pelayo-Teran et al. 2012). A review of empirical $G \times E$ studies using candidate genes in schizophrenia was published by Modinos et al. (2013).

For future $G \times E$ research in schizophrenia, it would be better to assess environmental variables quantitatively in a prospective way. The timing of environmental events is also important. Dimensions of schizophrenia should be monitored quantitatively. Important genes previously found in the GWA schizophrenia studies should be applied in $G \times E$ research into schizophrenia as well as schizophrenia endophenotypes. Epigenetic variables should likewise be studied (Moffitt et al. 2005; Jaffee & Price 2007; van Os et al. 2008; van Os & Rutten 2009; Modinos et al. 2013; Svrakic et al. 2013; EU-GEI 2014; Uher 2014).

In summary, well-powered and designed studies of $G \times E$ interactions and epigenetic studies are still missing.

Conclusion/outlook


The last few years resulted in the establishment of major new contributions to our knowledge of schizophrenia. The systematic identification of genetic variants throughout the genome opened new avenues to the biology of the disease. GWA studies identified new loci containing genes involved in pathophysiology. One interesting aspect is that the genetic overlap between schizophrenia and BD which has been debated upon for decades could be demonstrated on the molecular level. Many studies are under way to characterise these genetic variants and to find pathways of the disease. A next major milestone was the discovery of multiple microdeletions and microduplications involved in schizophrenia. It became clear that structural genetic variants also contribute to the disease, making them highly interesting targets for new pharmaceuticals. Especially interesting is the major overlap regarding the expressivity and thus clinical presentation or particular deletions or duplications. There is a whole neurodevelopmental spectrum including, besides schizophrenia, e.g., autism, intellectual disability, developmental delay, attention problems and speech delay, sometimes in combination with other physical manifestations. This observation raised many new questions regarding the diagnostic criteria of psychiatric diseases and the current classification in general. Although still in its infancy, whole-genome sequencing of large samples will become the standard in genetic research in the very near future. The hope is to detect even very rare variants that are possibly responsible for subsamples or subtypes of the diseases. Furthermore, integrated systems biology approaches integrating genomics, epigenomics, transcriptomics, proteomics and metabolomics may further contribute to the identification of the pathways contributing to schizophrenia, enabling a precision medicine approach to the treatment of individual patients. Whole-genome sequencing of very large samples and system biology applications have the potential to lead to the desperately needed precision medicine in individual patients.


Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

ORCID


Ina Giegling  <http://orcid.org/0000-0001-8407-7512>


Alessandro Serretti  <http://orcid.org/0000-0003-4363-3759>

David A. Collier  <http://orcid.org/0000-0003-4087-1559>

JamesL. Kennedy  <http://orcid.org/0000-0002-8733-3806>

Florence Thibaut  <http://orcid.org/0000-0002-0204-5435>

Sven Cichon  <http://orcid.org/0000-0002-9475-086X>

Dan Rujescu  <http://orcid.org/0000-0002-1432-313X>

References

- Abdelmoity AT, LePichon J-B, Nyp SS, Soden SE, Daniel CA, Yu S. 2012. 15q11.2 proximal imbalances associated with a diverse array of neuropsychiatric disorders and mild dysmorphic features. *J Dev Behav Pediatr.* 33:570–576.
- Adams CE, Yonchek JC, Schulz KM, Graw SL, Stitzel J, Teschke PU, Stevens KE. 2012. Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases. *Neuroscience.* 207:274–282.
- Agerbo E, Sullivan PF, Vilhjálmsson BJ, Pedersen CB, Mors O, Børglum AD, Hougaard DM, Hollegaard MV, Meier S, Mattheisen M, et al. 2015. Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis. *JAMA Psychiatry.* 72:635–641.
- Akbarian S. 2014. Epigenetic mechanisms in schizophrenia. *Dialogues Clin Neurosci.* 16:405–417.
- Bassett AS, McGillivray BC, Jones BD, Pantzar JT. 1988. Partial trisomy chromosome 5 cosegregating with schizophrenia. *Lancet.* 1:799–801.
- Beards S, Gayer-Anderson C, Borges S, Dewey ME, Fisher HL, Morgan C. 2013. Life events and psychosis: a review and meta-analysis. *Schizophr Bull.* 39:740–747.
- Cardno AG, Gottesman II. 2000. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. *Am J Med Genet.* 97:12–17.
- CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium, Psychosis Endophenotypes International Consortium. 2016. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet.* doi:10.1038/ng.3725 [Epub ahead of print].
- de Kovel CG, Trucks H, Helbig I, Mefford HC, Baker C, Leu C, Kluck C, Muhle H, von Spiczak S, Ostertag P, et al. 2010. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. *Brain.* 133:23–32.
- Derks EM, Ayub M, Chambert K, Del Favero J, Johnstone M, MacGregor S, Maclean A, McKechnie AG, McRae AF, Moran JL, et al. 2013. A genome wide survey supports the involvement of large copy number variants in schizophrenia with and without intellectual disability. *Am J Med Genet B Neuropsychiatr Genet.* 162B:847–854.
- EU-GEI. 2014. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. *Schizophr Bull.* 40:729–736.
- Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh PR, Anttila V, Xu H, Zang C, Farh K, et al. 2015. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet.* 47:1228–1235.
- Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM, et al.

2014. De novo mutations in schizophrenia implicate synaptic networks. *Nature*. 506:179–184.
- Gatt JM, Burton KL, Williams LM, Schofield PR. 2015. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. *J Psychiatr Res*. 60:1–13.
- Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, et al. 2011. Increased exonic de novo mutation rate in individuals with schizophrenia. *Nat Genet*. 43:860–863.
- Gottesman II, Laursen TM, Bertelsen A, Mortensen PB. 2010. Severe mental disorders in offspring with 2 psychiatrically ill parents. *Arch Gen Psychiatry*. 67:252–257.
- Grayton HM, Fernandes C, Rujescu D, Collier DA. 2012. Copy number variations in neurodevelopmental disorders. *Prog Neurobiol*. 99:81–91.
- Grozeva D, Conrad DF, Barnes CP, Hurles M, Owen MJ, O'Donovan MC, Craddock N, Kirov G, WTCCC. 2012. Independent estimation of the frequency of rare CNVs in the UK population confirms their role in schizophrenia. *Schizophr Res*. 135:1–7.
- Guha S, Rees E, Darvasi A, Ivanov D, Ikeda M, Bergen SE, Magnusson PK, Cormican P, Morris D, Gill M, Molecular Genetics of Schizophrenia Consortium; Wellcome Trust Case Control Consortium 2, et al. 2013. Implication of a rare deletion at distal 16p11.2 in schizophrenia. *JAMA Psychiatry*. 70:253–260.
- Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H, Consortium on the Genetics of Schizophrenia (COGS); PAARTNERS Study Group, Nimgaonkar VL, Go RC, Savage RM, Swerdlow NR, Gur RE, Braff DL, King MC, McClellan JM, et al. 2013. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. *Cell*. 154:518–529.
- Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, Zang C, Ripke S, Bulik-Sullivan B, Stahl E, Schizophrenia Working Group of the Psychiatric Genomics Consortium; SWE-SCZ Consortium, et al. 2014. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. *Am J Hum Genet*. 95:535–552.
- Haldeman-Englert CR, Jewett T. 1993–2016. 1q21.1 Recurrent Microdeletion. In Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean L JH, et al., editors. Seattle, WA: GeneReviews(R).
- Hamshere ML, Walters JT, Smith R, Richards AL, Green E, Grozeva D, Jones I, Forty L, Jones L, Gordon-Smith K, et al. 2013. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCAG8, and extensive replication of associations reported by the Schizophrenia PGC. *Mol Psychiatry*. 18:708–712.
- Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A, Muhle H, de Kovel C, Baker C, von Spiczak S, et al. 2009. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. *Nat Genet*. 41:160–162.
- Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, et al. 2011a. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. *Am J Psychiatry*. 168:408–417.
- Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, et al. 2011b. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. *Mol Psychiatry*. 16:17–25.
- International Schizophrenia Consortium. 2008. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature*. 455:237–241.
- International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P. 2009. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 460:748–752.
- Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2. 2012. Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. *Biol Psychiatry*. 72:620–628.
- Isles AR, Ingason A, Lowther C, Walters J, Gawlick M, Stöber G, Rees E, Martin J, Little RB, Potter H, et al. 2016. Parental origin of interstitial duplications at 15q11.2-q13.3 in schizophrenia and neurodevelopmental disorders. *PLoS Genet*. 12:e1005993.
- Jaffee SR, Price TS. 2007. Gene-environment correlations: a review of the evidence and implications for prevention of mental illness. *Mol Psychiatry*. 12:432–442.
- Jenkins AK, Paterson C, Wang Y, Hyde TM, Kleinman JE, Law AJ. 2016. Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging. *Mol Psychiatry*. 21:701–706.
- Kendler KSA. 2015. Joint history of the nature of genetic variation and the nature of schizophrenia. *Mol Psychiatry*. 20:77–83.
- Kennedy JL, Giuffra LA, Moises HW, Cavalli-Sforza LL, Pakstis AJ, Kidd JR, Castiglione CM, Sjogren B, Wetterberg L, Kidd KK. 1988. Evidence against linkage of schizophrenia to markers on chromosome 5 in a northern Swedish pedigree. *Nature*. 336:167–170.
- Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, O'Donovan MC, Erdogan F, Owen MJ, Ropers HH, et al. 2008. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. *Hum Mol Genet*. 17:458–465.
- Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, International Schizophrenia Consortium; Wellcome Trust Case Control Consortium, Craddock N, Owen MJ, O'Donovan MC. 2009a. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. *Hum Mol Genet*. 18:1497–1503.
- Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. 2009b. Neurexin 1 (NRXN1) deletions in schizophrenia. *Schizophr Bull*. 35:851–854.
- Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, Moran J, Chambert K, Toncheva D, Georgieva L, et al. 2012. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol Psychiatry*. 17:142–153.
- Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK. 2007. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. *Mol Psychiatry*. 12:572–580.
- Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin F, et al. 2011. Copy number

- variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry*. 168:302–316.
- Lichtenstein P, Björk C, Hultman CM, Scolnick E, Sklar P, Sullivan PF. 2006. Recurrence risks for schizophrenia in a Swedish national cohort. *Psychol Med*. 36:1417–1425.
- Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. 2009. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet*. 373:234–239.
- Malhotra D, Sebat J. 2012. CNVs: harbingers of a rare variant revolution in psychiatric genetics. *Cell*. 148:1223–1241.
- Maric NP, Svrakic DM. 2012. Why schizophrenia genetics needs epigenetics: a review. *Psychiatr Danub*. 24:2–18.
- Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, et al. 2008. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 82:477–488.
- McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastovshy O, et al. 2009. Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet*. 41:1223–1227.
- McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, Mistry M, Pavlidis P, Solomon R, Ghiban E, et al. 2014. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. *Mol Psychiatry*. 19:652–658.
- Millar JK, Christie S, Semple CA, Porteous DJ. 2000. Chromosomal location and genomic structure of the human translin-associated factor X gene (TRAX; TSNA) revealed by intergenic splicing to DISC1, a gene disrupted by a translocation segregating with schizophrenia. *Genomics*. 67:69–77.
- Miller BJ, Culpepper N, Rapaport MH, Buckley P. 2013. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. *Prog Neuropsychopharmacol Biol Psychiatry*. 42:92–100.
- Modinos G, Iyegbe C, Prata D, Rivera M, Kempton MJ, Valmaggia LR, et al. 2013. Molecular genetic gene-environment studies using candidate genes in schizophrenia: A systematic review. *Schizophr Res*. 150:356–365.
- Moffitt TE, Caspi A, Rutter M. 2005. Strategy for investigating interactions between measured genes and measured environments. *Arch Gen Psychiatry*. 62:473–481.
- Moreno-De-Luca D, Mulle JG, Kaminsky EB, Sanders SJ, GeneSTAR, Myers SM, Adam MP, Pakula AT, Eisenhauer NJ, Uhas K, SGENE Consortium, et al. 2010. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. *Am J Hum Genet*. 87:618–630.
- Muir WJ, Pickard BS, Blackwood DH. 2008. Disrupted-in-Schizophrenia-1. *Curr Psychiatry Rep*. 10:140–147.
- Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, Sobreira NL, Valle D, Rudd MK, Satten G, et al. 2010. Microdeletions of 3q29 confer high risk for schizophrenia. *Am J Hum Genet*. 87:229–236.
- Mulle JG, Pulver AE, McGrath JA, Wolyniec PS, Dodd AF, Cutler DJ, Sebat J, Malhotra D, Nestadt G, Conrad DF, et al. 2014. Reciprocal duplication of the Williams-Beuren syndrome deletion on chromosome 7q11.23 is associated with schizophrenia. *Biol Psychiatry*. 75:371–377.
- Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. 1986. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. *Cold Spring Harb Symp Quant Biol*. 51(Pt 1):263–273.
- Mullis KB, Ferré F, Gibbs RA. 1994. The polymerase chain reaction. Basel, Berlin, Boston: Birkhäuser.
- NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, et al. 2007. Replicating genotype-phenotype associations. *Nature*. 447:655–660.
- Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T, Riley B, Paunio T, Pulver AE, Irmansyah, et al. 2009. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. *Mol Psychiatry*. 14:774–785.
- O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskva V, Nikolov I, Hamshe M, Carroll L, Georgieva L, et al. 2008. Identification of loci associated with schizophrenia by genome-wide association and follow-up. *Nat Genet*. 40:1053–1055.
- Owen MJ, Sawa A, Mortensen PB. 2016. Schizophrenia. *Lancet*. S0140-6736:01121–01126.
- Pagnamenta AT, Wing K, Sadighi Akha E, Knight SJ, Bölte S, Schmötzler G, Duketis E, Poustka F, Klauck SM, Poustka A, International Molecular Genetic Study of Autism Consortium, et al. 2009. A 15q13.3 microdeletion segregating with autism. *Eur J Hum Genet*. 17:687–692.
- Pelayo-Teran JM, Suarez-Pinilla P, Chadi N, Crespo-Facorro B. 2012. Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. *Curr Pharmaceutical Design*. 18:5024–5035.
- Perkins DO, Jeffries C, Sullivan P. 2005. Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. *Mol Psychiatry*. 10:69–78.
- Pocklington AJ, Rees E, Walters JT, Han J, Kavanagh DH, Chambert KD, Holmans P, Moran JL, McCarroll SA, Kirov G, et al. 2015. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. *Neuron*. 86:1203–1214.
- Porteous DJ, Thomson PA, Millar JK, Evans KL, Hennah W, Soares DC, McCarthy S, McCombie WR, Clapcote SJ, Korth C, et al. 2014. DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan. *Mol Psychiatry*. 19:141–143.
- Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, Morrow B, Karayiorgou M, Antonarakis SE, Housman D, et al. 1994. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. *J Nerv Ment Dis*. 182:476–478.
- Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kähler A, et al. 2014. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature*. 506:185–190.
- Randall AD, Kurihara M, Brandon NJ, Brown JT. 2014. Disrupted in schizophrenia 1 and synaptic function in the mammalian central nervous system. *Eur J Neurosci*. 39:1068–1073.
- Raux G, Bumsel E, Hecketsweiler B, van Amelsvoort T, Zinkstok J, Manouvrier-Hanu S, Fantini C, Brévière GM, Di Rosa G, Pustorino G, et al. 2007. Involvement of hyperproliferation in cognitive and psychiatric features of the 22q11 deletion syndrome. *Hum Mol Genet*. 16:83–91.

- Rees E, Walters JT, Georgieva L, Isles AR, Chambert KD, Richards AL, Mahoney-Davies G, Legge SE, Moran JL, McCarroll SA, et al. 2014. Analysis of copy number variations at 15 schizophrenia-associated loci. *Br J Psychiatry*. 204:108–114.
- Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, et al. 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet*. 45:1150–1159.
- Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Touloupoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, et al. 2009. Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet*. 18:988–996.
- Rutter M, Moffitt TE, Caspi A. 2006. Gene-environment interplay and psychopathology: multiple varieties but real effects. *J Child Psychol Psychiatry*. 47:226–261.
- Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicek AE, Murtha MT, Bal VH, Bishop SL, Dong S, et al. 2015. Insights into autism spectrum disorder genomic architecture and biology from 71 Risk Loci. *Neuron*. 87:1215–1233.
- Schaaf CP, Boone PM, Sampath S, Williams C, Bader PI, Mueller JM, Shchelochkov OA, Brown CW, Crawford HP, Phalen JA, et al. 2012. Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions. *Eur J Hum Genet*. 20:1240–1247.
- Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. 2011. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet*. 43:969–976.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 511:421–427.
- Schmitt A, Rujescu D, Gawlik M, Hasan A, Hashimoto K, Iceta S, Jarema M, Kambeitz J, Kasper S, Keeser D, WFSBP Task Force on Biological Markers, et al. 2016. Consensus paper of the WFSBP task force on biological markers: criteria for biomarkers and endophenotypes of schizophrenia part II: cognition, neuroimaging and genetics. *World J Biol Psychiatry*. 17:406–428.
- Schneider M, Debbané M, Bassett AS, Chow EW, Fung WL, van den Bree M, Owen M, Murphy KC, Niarchou M, Kates WR, International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome, et al. 2014. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *Am J Psychiatry*. 171:627–639.
- Shih RA, Belmonte PL, Zandi PP. 2004. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. *Int Rev Psychiatry*. 16:260–283.
- Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, et al. 2016. Schizophrenia risk from complex variation of complement component 4. *Nature*. 530:177–183.
- Sherrington R, Brynjolfsson J, Petursson H, Potter M, Dudleston K, Barraclough B, Wasmuth J, Dobbs M, Gurling H. 1988. Localization of a susceptibility locus for schizophrenia on chromosome 5. *Nature*. 336:164–167.
- Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, et al. 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature*. 460:753–757.
- Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW. 1992. Late-onset psychosis in the velo-cardio-facial syndrome. *Am J Med Genet*. 42:141–142.
- Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J, Suvisaari J, Chheda H, Blackwood D, Breen G, et al. 2016. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat Neurosci*. 19:571–577.
- Squarcione C, Torti MC, Di Fabio F, Biondi M. 2013. 22q11 deletion syndrome: a review of the neuropsychiatric features and their neurobiological basis. *Neuropsychiatr Dis Treat*. 9:1873–1884.
- St Clair D, Blackwood D, Muir W, Baillie D, Hubbard A, Wright A, Evans HJ. 1989. No linkage of chromosome 5q11-q13 markers to schizophrenia in Scottish families. *Nature*. 339:305–309.
- St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C, Evans HJ. 1990. Association within a family of a balanced autosomal translocation with major mental illness. *Lancet*. 336:13–16.
- Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, et al. 2008. Large recurrent microdeletions associated with schizophrenia. *Nature*. 455:232–236.
- Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, et al. 2009. Common variants conferring risk of schizophrenia. *Nature*. 460:744–747.
- Steinberg S, de Jong S, Mattheisen M, Costas J, Demontis D, Jamain S, Pietiläinen OP, Lin K, Papiol S, Huttenlocher J, et al. 2014. Common variant at 16p11.2 conferring risk of psychosis. *Mol Psychiatry*. 19:108–114.
- Sullivan PF, Kendler KS, Neale MC. 2003. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 60:1187–1192.
- Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, et al. 2008. Genomewide association for schizophrenia in the CATIE study: results of stage 1. *Mol Psychiatry*. 13:570–584.
- Svrakic DM, Zorumski CF, Svrakic NM, Zwir I, Cloninger CR. 2013. Risk architecture of schizophrenia: the role of epigenetics. *Curr Opin Psychiatry*. 26:188–195.
- Szyf M. 2015. Epigenetics, a key for unlocking complex CNS disorders? Therapeutic implications. *Eur Neuropsychopharmacol*. 25:682–702.
- Uher R. 2014. Gene-environment interactions in severe mental illness. *Front Psychiatry*. 5:48
- van Dongen J, Boomsma DI. 2013. The evolutionary paradox and the missing heritability of schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 162B:122–136.
- van Os J, Rutten BPF. 2009. Gene-environment-wide interaction studies in psychiatry. *Am J Psychiatry*. 166:964–966.
- van Os J, Rutten BPF, Poulton R. 2008. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. *Schizophr Bull*. 34:1066–1082.
- van Winkel R, Stefanis NC, Myin-Germeys I. 2008. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. *Schizophr Bull*. 34:1095–1105.

- Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon S, Bhandari A, Corominas R, et al. 2011. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature*. 471:499–503.
- Vieland VJ, Walters KA, Lehner T, Azaro M, Tobin K, Huang Y, Brzustowicz LM. 2014. Revisiting schizophrenia linkage data in the NIMH Repository: reanalysis of regularized data across multiple studies. *Am J Psychiatry*. 171:350–359.
- Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science*. 320:539–543.
- Waterland RA, Jirtle RL. 2003. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol Cell Biol*. 23:5293–5300.
- Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, Gill M, Thapar A, O'Donovan MC, Owen MJ, Holmans P, et al. 2012. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. *Am J Psychiatry*. 169:195–204.
- Wong AH, Gottesman II, Petronis A. 2005. Phenotypic differences in genetically identical organisms: the epigenetic perspective. *Hum Mol Genet*. 14:R11–18.
- Wray NR, Gottesman II. 2012. Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. *Front Genet*. 3:118.
- Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. 2014. Research review: polygenic methods and their application to psychiatric traits. *J Child Psychol Psychiatry*. 55:1068–1087.
- Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. 2008. Strong association of de novo copy number mutations with sporadic schizophrenia. *Nat Genet*. 40:880–885.
- Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, Gogos JA, Karayiorgou M. 2011. Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat Genet*. 43:864–868.
- Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y, Levy S, Gogos JA, Karayiorgou M. 2012. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat Genet*. 44:1365–1369.